Grant ID DP240073
Awarded On November 15, 2023
Title Advancing Clinical Development of MB-105 CD5 CAR-T cell Therapy for T-cell Lymphoma
Program Product Development Research
Award Mechanism Texas Therapeutics Company Awards for Product Development Research
Institution/Organization March Biosciences, Inc.
Principal Investigator/Program Director Sarah Hein
Cancer Sites Leukemia, Lymphoma
Contracted Amount $13,358,637*

*Pending contract negotiation

Lay Summary

March Biosciences, Inc is a Houston-based clinical-stage cell therapy company with a mission to address relapsed and recurrent T-cell lymphoma, an orphan indication with few treatment options and extremely poor patient outcomes. Despite the clear success of chimeric antigen receptor (CAR) T-cell therapy in B-cell lymphoma and leukemia, no CAR T-cell therapies are approved for T-cell cancers due to the risk of toxicity for normal T-cells, leading to catastrophic immunodeficiency. The scientific founders of March Biosciences have developed and optimized a CD5-directed CAR T-cell therapy, MB-105, currently in a Phase 1 trial at Baylor College of Medicine. Early trial results have shown a favora...

Read More